Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1612
    -0.0071 (-0.61%)
     

  • GBP/USD

    1.2371
    -0.0068 (-0.54%)
     

  • Bitcoin GBP

    51,847.96
    +662.42 (+1.29%)
     

  • CMC Crypto 200

    1,383.48
    +70.86 (+5.40%)
     

  • S&P 500

    4,960.35
    -50.77 (-1.01%)
     

  • DOW

    37,953.47
    +178.09 (+0.47%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,407.30
    +9.30 (+0.39%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Why Novo Nordisk Stock Is Falling Today

George Budwell, The Motley Fool
·2-min read
Why Novo Nordisk Stock Is Falling Today

Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong mid-stage data for Pfizer's orally administered diabetes and weight loss drug, danuglipron, which were published yesterday in JAMA Network medical journal. Novo's shares have more than doubled in value over the prior two years, thanks to the breakout success of its type 2 diabetes and weight loss drug semaglutide.

Continue reading